Ethnobotanical Significance and Traditional uses of Vernonia Amygdalina (Bitter Leaf): A Comprehensive Review

Abstract

Vernonia amygdalina Delile (Asteraceae), commonly known as bitter leaf, is a culturally and medically significant African ethnobotanical resource used widely as both food and medicine. Despite its ubiquity across West, Central, and East Africa, knowledge of its applications, phytochemistry, and pharmacology remains fragmented across disparate local surveys and laboratory studies. This review synthesizes ethnobotanical records, phytochemical profiles, pharmacological findings, and toxicological evidence to provide a comprehensive understanding of V. amygdalina and identify priority areas for future research. Ethnobotanical data reveal broad applications, including treatment of malaria, gastrointestinal disorders, helminth infections, diabetes, wounds, postpartum conditions, and use in cultural rituals. Preparation methods—such as leaf washing, crushing, decoction, infusion, and topical poultices—reflect both culinary and medicinal traditions. Key phytochemicals include sesquiterpene lactones (e.g., vernolide, vernodalol, vernodalin), flavonoids (e.g., luteolin and luteolin-7-O-glucoside), phenolic acids, saponins, tannins, and alkaloids. These constituents exhibit antimalarial, antimicrobial, antidiabetic, anticancer, hepatoprotective, anti-inflammatory, and antioxidant activities in experimental models. However, clinical validation remains limited to a single controlled malaria trial demonstrating partial symptomatic relief but inadequate parasite clearance. Toxicological studies indicate low acute toxicity at dietary and traditional-use doses, though high-dose or prolonged exposure may elicit hepatic or renal stress, and isolated sesquiterpene lactones show cytotoxicity at micromolar concentrations. Safety concerns also arise from potential contamination of commercial dried leaf products. Conservation and sustainability challenges include overharvesting of wild stocks, habitat pressure, and variable phytochemical quality linked to environmental factors. Major knowledge gaps include region-specific ethnobotanical documentation, standardized dosing, mechanistic pharmacology, chronic toxicity, reproductive safety, and genetic diversity mapping. Future research should prioritize multi-center clinical trials, integrated omics approaches, cultivation and conservation programs, and value-chain improvement for safe commercialization. Overall, V. amygdalina represents a compelling example of “food-as-medicine,” offering nutraceutical, pharmacological, and socio-economic potential. Its sustainable development will require coordinated interdisciplinary approaches that respect traditional knowledge while applying modern scientific rigor.